Conference Call with Mankind Pharma Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Mankind Pharma announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from Operations at Rs 3,077 crore, up by 14% YoY. Domestic revenue at Rs 2,796 crore, up by 11% YoY; Exports at Rs 281 crore, up by 57% YoY. Reported EBITDA margin of 27.7% and PAT margin of 21.4%. Diluted EPS of Rs 16.3, up by 30% YoY (FV Re.1). H1FY25 Financial Highlights: Revenue from Operations at Rs 5,970 crore, up by 13% YoY. Domestic revenue at Rs 5,430 crore, up by 10% YoY; Export at Rs 540 crore, up by 59% YoY. Reported EBITDA margin at 25.8%, up by 14% YoY with Adj. EBITDA margin of 26.5% and PAT margin of 20.1%. Diluted EPS of Rs 29.7, up by 20% YoY (FV Re.1). Rajeev Juneja, Vice Chairman & Managing Director, Mankind Pharma, said: “We are pleased to report steady revenue growth of 13.6% YoY with strong EBITDA margins of 27.7%, driven by recovery in volume, continued outperformance in chronic segment and operating leverage. OTC business has been carved out to a WOS2 of Mankind Pharma. From Q3, this business has embarked on the journey towards its next phase of growth. Our acquisition of BSV perfectly aligns with our vision to expand into a high entry barrier portfolio with the #1 player in the gynaecology segment, leadership in certain critical care products, and further enhance our R&D; capabilities. Multiple growth levers – resilient base business, fast growing specialty chronic segment, high potential OTC business, and high-entry barrier super specialty portfolio of BSV. Together, these levers will propel our growth journey ahead. “ Result PDF